Overseas medical insurance customers could be interested to learn that the drug tamoxifen may protect against breast cancer.
Indeed, research published in Cancer, a peer-reviewed journal of the American Cancer Society, found that the drug's preventative effects can last long after treatment has finished.
However, the range of side effects mean that not everybody stands to benefit from the drug in this manner.
Overseas medical insurance customers could discuss the matter with their doctor if they are curious, but Dr Peter Aplerin, who researched the drug with his colleagues at Archimedes Inc, said that post-menopausal women aged 55 years and younger with a five-year risk of developing breast cancer of 1.66 per cent or greater stand to benefit most from using tamoxifen as a preventative measure against breast cancer.
He explained that in this group of people it will "save lives and has a low frequency of side effects".